SCHEMBL20896372

SCHEMBL20896372

CC(=O)Nc1ncc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
PDGFRB P09619 3/20 0.42
KDR P35968 3/20 0.42
ROCK2 O75116 1/20 0.40
FFAR1 O14842 1/20 0.39
CYP1A2 P05177 2/20 0.37
CA1 P00915 4/20 0.36
CA2 P00918 4/20 0.36
CA9 Q16790 4/20 0.36
PTK2 Q05397 1/20 0.36
GAA P10253 1/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799957 0.87 PDGFRB (0.44) DGAT1GSK3AGSK3BPDGFRBKDR
Carbamic Acid SCHEMBL17997310 0.83 PDGFRB (0.45) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL30831522 0.81 PTK2 (0.51) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL1181203 0.81 PTK2 (0.51) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL1553789 0.81 GSK3A (0.44) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL1180976 0.80 AAK1 (0.47) DGAT1GSK3AGSK3BPDGFRBKDR
Isobutane SCHEMBL16465194 0.80 PDGFRB (0.42) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL336629 0.78 FFAR1 (0.41) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL1841804 0.77 DGAT1 (0.43) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL2179248 0.77 DGAT1 (0.41) DGAT1GSK3AGSK3BPDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 US disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
EP-4351560-A1 ANTICANCER COMPOUNDS The Regents of the University of California (US) 2024-04-17 EP disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 CN disclosed
US-20230219926-A1 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING FACIT INC. (CA) 2023-07-13 US disclosed
US-20230025178-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-01-26 US disclosed
WO-2022261204-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-15 WO disclosed
EP-3423451-B1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING PROPELLON THERAPEUTICS INC (CA) 2022-08-17 EP disclosed
CN-109195965-B Inhibitors of WDR5 protein-protein binding 普罗佩纶治疗公司 2022-07-26 CN disclosed
US-11319299-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2022-05-03 US disclosed
US-20190112290-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING Propellon Therapeutics Inc. (CA) 2019-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319299-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 DGAT1 2190/4885GSK3A 2521/4885GSK3B 2541/4885
US-20250179059-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA DGAT1 2299/4885GSK3A 1916/4885GSK3B 1569/4885
US-20230025178-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA DGAT1 2299/4885GSK3A 1916/4885GSK3B 1569/4885
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 DGAT1 2190/4885GSK3A 2521/4885GSK3B 2541/4885
US-20190112290-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 DGAT1 2302/4885GSK3A 2339/4885GSK3B 2232/4885
US-20230219926-A1 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 DGAT1 2190/4885GSK3A 2521/4885GSK3B 2541/4885
US-12162870-B2 Anticancer compounds BET1, BRD4, BICRA DGAT1 2299/4885GSK3A 1916/4885GSK3B 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.